Perampanel: Medical Alternative for Essential Tremor?

IF 0.8 4区医学 Q4 CLINICAL NEUROLOGY Clinical Neuropharmacology Pub Date : 2023-03-01 DOI:10.1097/WNF.0000000000000541

Lola Díaz-Feliz, Cici Feliz-Feliz, Javier Del Val, Marta Ruiz-López, Pedro J García-Ruiz

{"title":"Perampanel: Medical Alternative for Essential Tremor?","authors":"Lola Díaz-Feliz, Cici Feliz-Feliz, Javier Del Val, Marta Ruiz-López, Pedro J García-Ruiz","doi":"10.1097/WNF.0000000000000541","DOIUrl":null,"url":null,"abstract":"Objectives: The aim of this study was to assess the safety and efficacy of perampanel in patients with refractory essential tremor (ET).Methods: We recruited patients from our movement disorders clinic with the diagnosis of severe refractory ET, and perampanel 4 mg at night was initiated.Assessments were conducted at baseline and after 1 month of treatment with perampanel 4 mg/d. Details about tolerance and effectiveness were collected. Clinical evaluation was conducted with the Fahn-Tolosa-Marín scale, and statistical analysis was carried out with Wilcoxon matched pairs signed rank test.Results: This study included 18 patients with severe ET (11 females, 7 males; mean age: 75.1 ± 12.03 years; mean duration of ET: 17.4 ± 17.03 years). Perampanel significantly improved patients' average score with refractory ET ( P ≤ 0.0001). This improvement has been occasionally quite relevant. However, a proportion of patients did not tolerate perampanel because of several adverse effects including dizziness, ataxia, irritability, and instability.Conclusions: Perampanel had a markedly positive antitremor effect in patients with ET and could be an alternative treatment. However, this drug is not devoid of adverse effects.","PeriodicalId":10449,"journal":{"name":"Clinical Neuropharmacology","volume":"46 2","pages":"51-54"},"PeriodicalIF":0.8000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/WNF.0000000000000541","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The aim of this study was to assess the safety and efficacy of perampanel in patients with refractory essential tremor (ET).

Methods: We recruited patients from our movement disorders clinic with the diagnosis of severe refractory ET, and perampanel 4 mg at night was initiated.Assessments were conducted at baseline and after 1 month of treatment with perampanel 4 mg/d. Details about tolerance and effectiveness were collected. Clinical evaluation was conducted with the Fahn-Tolosa-Marín scale, and statistical analysis was carried out with Wilcoxon matched pairs signed rank test.

Results: This study included 18 patients with severe ET (11 females, 7 males; mean age: 75.1 ± 12.03 years; mean duration of ET: 17.4 ± 17.03 years). Perampanel significantly improved patients' average score with refractory ET ( P ≤ 0.0001). This improvement has been occasionally quite relevant. However, a proportion of patients did not tolerate perampanel because of several adverse effects including dizziness, ataxia, irritability, and instability.

Conclusions: Perampanel had a markedly positive antitremor effect in patients with ET and could be an alternative treatment. However, this drug is not devoid of adverse effects.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

特发性震颤的医疗选择?

目的:本研究的目的是评估perampanel在难治性特发性震颤(ET)患者中的安全性和有效性。方法:我们从我们的运动障碍诊所招募诊断为严重难治性ET的患者，并开始使用perampanel 4mg每晚。在基线和使用perampanel 4mg /d治疗1个月后进行评估。收集耐受性和有效性的详细信息。临床评价采用Fahn-Tolosa-Marín量表，统计分析采用Wilcoxon配对双符号秩检验。结果:本研究纳入18例重度ET患者(女11例，男7例;平均年龄:75.1±12.03岁;ET平均持续时间:17.4±17.03年)。Perampanel显著提高难治性ET患者的平均评分(P≤0.0001)。这种改进有时是非常相关的。然而，一部分患者不能耐受perampanel，因为一些不良反应，包括头晕、共济失调、易怒和不稳定。结论:Perampanel对ET患者有明显的积极的抗震颤作用，可以作为一种替代治疗方法。然而，这种药物并非没有副作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Neuropharmacology 医学-临床神经学

CiteScore

1.20

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical Neuropharmacology is a peer-reviewed journal devoted to the pharmacology of the nervous system in its broadest sense. Coverage ranges from such basic aspects as mechanisms of action, structure-activity relationships, and drug metabolism and pharmacokinetics, to practical clinical problems such as drug interactions, drug toxicity, and therapy for specific syndromes and symptoms. The journal publishes original articles and brief reports, invited and submitted reviews, and letters to the editor. A regular feature is the Patient Management Series: in-depth case presentations with clinical questions and answers.